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diagnosis of microcystic adnexal
carcinoma, desmoplastic
trichoepithelioma and morpheaform
basal cell carcinoma using BerEP4
and stem cell markers
Background: Microcystic adnexal carcinoma (MAC), desmoplastic
trichoepithelioma (DTE) and morpheaform basal cell carcinoma (BCC)
frequently impose a considerable differential diagnostic challenge and
immunohistochemistry is often used as a differentiating diagnostic
adjunct.
Methods: Using standard immunohistochemical techniques, we
examined 21 examples of DTE, 17 examples of morpheaform BCC
and 10 examples of MAC for the expression of BerEP4, a marker of
epithelial cells, and of three stem cell markers, pleckstrin homology-like
domain, family A, member 1 (PHLDA1) [T cell death-associated gene
51 (TDAG51)], cytokeratin 15 (CK15) and cytokeratin (CK19).
Results: All but one MAC was negative for BerEP4 and all
morpheaform BCC expressed BerEP4. Sixteen out of 21 DTE were
immunoreactive for BerEP4. All 21 DTE were PHLDA1 positive and
all 17 morpheaform BCC were PHLDA1 negative. MAC showed a
mixed staining pattern for PHLDA1. CK15 was expressed in 20/21
DTE, whereas the majority of cases of MAC and morpheaform BCC
were CK15 negative. CK19 stained more MAC than DTE and
morpheaform BCC.
Conclusions: BerEP4 differentiates between MAC and
morpheaform BCC but not between MAC and DTE whereas
PHLDA1 differentiates between DTE and morpheaform BCC but
shows variable staining in MAC. CK15 and CK19 are helpful adjuncts
in the differential diagnosis of sclerosing adnexal neoplasms but are
second in line to BerEP4 and PHLDA1. We propose an algorithm for
the immunohistochemical work-up of sclerosing adnexal neoplasms.
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Sclerosing adnexal neoplasms, most importantly
microcystic adnexal carcinoma (MAC), desmoplastic
trichoepithelioma (DTE) and morpheaform basal
cell carcinoma (BCC), belong to a group of
tumors in dermatopathology that frequently impose
a considerable differential diagnostic challenge. A
misdiagnosis can either lead to unnecessary extensive
surgery or to insufficient treatment.
Immunohistochemistry is often used as a
diagnostic adjunct to differentiate between these
neoplasms. Among the most commonly employed
markers are cytokeratin 7 (CK7), cytokeratin 15
(CK15), cytokeratin 19 (CK19), cytokeratin 20
(CK20), the androgen receptor and BerEP4.1– 7
Two other proteins were recently introduced into
the literature which seem to differentiate between
DTE and morpheaform BCC with a high degree of
reliability, namely the fibroblast-activation protein8
and the low-affinity p75 neurotrophin receptor
(p75NTR).9 In the latter two studies, MAC was not
evaluated. The number of markers employed in the
literature in an attempt to distinguish between DTE
and morpheaform BCC increases exponentially
if the conventional variants of these tumors are
considered.4
The monoclonal antibody BerEP4 is an epithelial
marker that recognizes two glycopolypeptides (34
and 39 kDa).10 It differentiates with a high degree
of reliability between BCC and cutaneous squamous
cell carcinoma (SCC).11 – 15 In a previous study, we
showed that it also reliably differentiates between
MAC and morpheaform BCC in that it is negative in
the former and positive in the latter.4 Since a recent
publication5 contested that finding, in this study, we
repeated staining for BerEP4 on an additional 10
cases of MAC and 17 cases of morpheaform BCC
and found an identical staining pattern, supporting
our previous results. We also examined 21 cases of
DTE.
One of the most exciting developments in
contemporary dermatopathology is the use of
stem cell markers, to elucidate the histogenesis of
cutaneous neoplasms. As previously noted, CK15
and CK19 have already been employed in the
differential diagnosis of sclerosing adnexal neoplasms
and both are stem cell markers, with CK15 being
more specific than CK19.16 In this study on
MAC, DTE and morpheaform BCC, we compared
their staining patterns with that of one of the
newest members of the ever increasing arsenal of
stem cell markers, PHLDA1 (pleckstrin homology-
like domain, family A, member 1), also known
as TDAG51 (T cell death-associated gene 51).
PHLDA1 has been found to be twice as much
expressed in the human anagen bulge than CK15,17





Fig. 1. Staining for BerEP4 in MAC, DTE and morpheaform
BCC. Arrows in (A), (B) and (E) indicate positive internal control
(eccrine glands). Arrowhead in (E) indicates positive internal control
(secondary hair germ). Original magnifications: (A) ×25; (C), (E), (G)
×50; (B), (D), (F), (H) ×200.
stem cells.18,19 PHLDA1 reliably discriminates
between DTE and morpheaform BCC.20 It is highly
expressed in the former, but negative in the latter.
It has also proven its usefulness in the evaluation
of small biopsies of conventional trichoepithelioma
(TE) and BCC21 but has not been employed yet in
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MAC. Therefore, its differential diagnostic potential
in MAC compared to morpheaform BCC and DTE
is thus far unknown.
In this study, we evaluated the combined use of
BerEP4, PHLDA1 (TDAG51), CK15 and CK19




We examined 21 cases of DTE, 17 morpheaform
BCC and 10 MAC. The specimens were
retrieved from the archives of Dermatopathologie,
Friedrichshafen, Germany, the Department of
Pathology, Medical Center of the University of
Michigan, Ann Arbor, MI, USA and Nelson
Dermatopathology Associates, Atlanta, GA, USA.
The tissues were fixed in 10% neutral-buffered
formalin and subjected to routine processing and
paraffin embedding.
Immunohistochemical staining
Four-micron sections were placed on Colorfrost
Plus® slides (Erie Scientific LLC, Portsmouth, NH,
USA), deparaffinized in Bond® Dewax solution
(Leica Microsystems Ltd, Newcastle Upon Tyne,
UK) and dehydrated in decreasing concentrations
of ethanol. Prior to incubation with the primary
antibody, we used heat-induced epitope retrieval.
The retrieval conditions depended on each of the
four different antibodies employed. The antibodies
were directed against BerEP4, PHLDA1, CK 15
and CK19. All incubation conditions, antibody
specifications and positive controls are listed in
Table 1. As negative control, we used a scalp
sample from an excision of a trichilemmal cyst and
omitted the primary antibody. Color products were
developed using the Bond™ Polymer Refine Red
Detection Kit (Alkaline Phosphatase/RED, Cat #
DS9390, Leica Microsystems Ltd). The sections were
counterstained with hematoxylin before dehydration
and cover slipping. All procedures were done
on the Leica Bond-III Automatic Stainer (Leica
Microsystems Ltd).
Results
BerEP4 differentiates between MAC and morpheaform BCC
but not between MAC and DTE
All but one of the MAC were negative for BerEP4
and the single positive case showed less than
26% immunoreactive cells (Table 2; Fig. 1A,B).





Fig. 2. Staining for pleckstrin homology-like domain, family A,
member 1 (PHLDA1) in microcystic adnexal carcinoma (MAC),
desmoplastic trichoepithelioma and morpheaform basal cell
carcinoma. Arrows in (C) indicate the location of tumor cells of
MAC. Arrowheads in (C) and (G) indicate positive internal control
[vellus hairs in (C) and (G) and also eccrine gland in (G)]. Arrows in
(H) indicate scattered positive cells representing PHLDA1-positive
melanocytes. Original magnifications: (A) ×25; (C), (E), (G) ×50;
(B), (D), (F), (H) ×200.
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Table 1. Monoclonal antibodies utilized
Antibody Clone Dilution Manufacturer Epitope retrieval Positive control
BerEP4 VU-1D9 RTU Leica Microsystems Ltd
(PW31) Newcastle
Upon Tyne, UK
















Citrate buffer* pH 6.0;
20 min
Internal




Citrate buffer* pH 6.0;
20 min
Internal
CK105, cytokeratin 15; CK19, cytokeratin 19; PHLDA1, pleckstrin homology-like domain, family A, member 1; RTU, ready-to-use primary
antibody solution.
*Bond Epitope Retrieval Solution 1 (AR9961; Leica Microsystems Ltd).
†Bond Epitope Retrieval Solution 2 (AR9640; Leica Microsystems Ltd).
positive, with 16 cases revealing immunoreactivity in
over 75% and one case in over 25% of cells (Table 2;
Fig. 1G,H). In 16 cases of DTE staining for BerEP4,
the number of positive cells varied between one and
over 75%; five DTE were immunonegative (Table 2;
Fig. 1C–F).
PHLDA1 differentiates between DTE and morpheaform BCC
but shows variable staining in MAC
All 21 DTE were PHLDA1 positive and all
17 morpheaform BCC were PHLDA1 negative
(Table 2; Fig. 2E–H). Six of the MAC were PHLDA1
positive and three were PHLDA1 negative (Table 2;
Fig. 2A–D). The number of positive cells varied
between less than 26% and over 75% in MAC.
More DTE than MAC and morpheaform BCC are positive for
cytokeratin 15
CK15 is expressed in 20 of the 21 DTE examined
(Table 2; Fig. 3C,D). Nineteen of the 20 CK15-
positive cases showed immunoreactivity in over
75% of the neoplastic cells and one case in over
25% of cells. Nine of the 17 morpheaform BCC
were CK15 negative (Table 2; Fig. 3E,F) and
in two more less than 25% of cells were CK15
positive. Only 6/17 cases of morpheaform BCC
showed immunoreactivity for CK15 in more than
75% of cells. MAC also did not expressed CK15
in the majority of cases. Five cases were CK15
negative and in three cases less than 25% cells were
immunoreactive (Table 2; Fig. 3A,B).
High expression of cytokeratin 19 favors MAC over DTE and
morpheaform BCC
All MAC were CK19 positive with seven showing
immunoreactivity in more than 75% of cases
(Table 2; Fig. 4A,B). Out of the 21 cases of DTE,
nine were completely CK19 negative and 10 showed
immunopositivity in less than 25% of the cells
(Table 2; Fig. 4C,D). In morpheaform BCC, 10
cases were CK19 negative and 5/17 were CK19
positive in over 75% of the tumor cells (Table 2;
Fig. 4E,F).
Discussion
MAC, DTE and morpheaform BCC display over-
lapping histopathologic features in hematoxylin- and
eosin-stained sections. Thus, immunohistochemistry
has evolved as an adjunct in the often difficult differ-
ential diagnosis of these three sclerosing neoplasms.
Not a single marker, however, is able to differentiate
all three of them and a battery of antibodies is fre-
quently employed. In this study, we used a marker
of epithelial cells (BerEP4) as well as three follicular
stem cell markers (PHLDA1, CK15 and CK19).
BerEP4 is known for its intense labeling of BCC
and the lack thereof in SCC.11 – 15 In a previous
study on 13 cases of MAC, not a single neoplasm
was immunoreactive for BerEP4 whereas all 28
morpheaform BCC stained for BerEP4.4 The results
of this study on an additional 10 cases of MAC
corroborate these previous findings although 1 of
10 MAC was BerEP4 positive, albeit in less than
25% of the tumor cells. Therefore, combining both
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Fig. 3. Staining for cytokeratin 15 in microcystic adnexal carcinoma
(MAC), desmoplastic trichoepithelioma and morpheaform basal cell
carcinoma. Arrows in (A) indicate the location of tumor cells of MAC.
Arrowheads in (A) indicate positive internal control (transversely cut
bulge of hair follicles). Arrow in (F) indicate positive internal control
(hair follicle). Original magnifications: (A) ×25; (C, E) ×50; (B, D,
F) ×200.
studies revealed immunoreactivity for BerEP4 in
22/23 cases of MAC. Our results contradict a recent
study on 13 cases of MAC that found five tumors to
be BerEP4 positive and the remaining eight showing
no immunoreactivity.5 Intriguingly, the authors also
reported 3/8 SCCs staining for BerEP4.5 The latter
result is in disagreement with the literature. Five
other studies found all 23,13 22,22 21,11 6,23 and
324 cases of SCC (combined 75 cases) to be BerEP4
negative. Not a single case of SCC was positive
for BerEP4. Therefore, it is likely that technical
differences in the study by Hoang et al.5 lead to
BerEP4 immunoreactivity not only in SCCs but also




Fig. 4. Staining for cytokeratin 19 in MAC, DTE and morpheaform
BCC. Arrows in (C) indicate positive internal control (eccrine glands).
Arrow in (D) indicate positive internal control (intradermal duct of
eccrine gland). Arrows in (E, F) indicate positive internal control
(hair follicles). Original magnifications: (A) ×25; (C, E) ×50; (B, D,
F) ×200.
positive. On the basis of our current and previous4
study, we consider BerEP4 as a reliable differential
diagnostic tool to differentiate between MAC and
DTE. However, it does not allow differentiating
between MAC and DTE. Five out of 21 cases of DTE
were also BerEP4 negative. Previously, we reported
a similar number (4/16 DTE BerEP4 negative).4
PHLDA1 (TDAG51), a recently described
follicular stem cell marker discovered with
DNA microarrays,17 has been shown to reliably
differentiate not only TE and BCC in small biopsy
specimens21 but also DTE from morpheaform
BCC.20 In addition, its staining pattern confirmed
the nature of fibroepithelioma of Pinkus as a BCC
with a tumor-specific type of epidermal hyperplasia25
368
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BerEp4
+ –
DTE or BCC MAC or DTE
PHLDA 1 PHLDA1
+ – + –
DTE BCC MAC or DTE MAC
CK15+/CK19– CK15+ or –/CK19+ or –
CK15–/CK19+ CK15+/CK19– 
MAC DTE
Fig. 5. Algorithm for the immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and
morpheaform basal cell carcinoma utilizing BerEP4 and stem cell markers pleckstrin homology-like domain, family A, member 1, cytokeratin
15 and cytokeratin 19.
as opposed to a fenestrated trichoblastoma.26 In this
study, PHLDA1 was confirmed as a powerful tool
to differentiate between DTE and morpheaform
BCC. All DTE were PHLDA1 positive and all
morpheaform BCC were PHLDA1 negative (with
the exception of one case in which less than
26% of morpheaform BCC tumor cells were
immunoreactive). However, PHLDA1 showed an
inconsistent staining pattern in MAC. Three tumors
were PHLDA1 negative and six were positive. The
PHLDA1-positive MAC showed variable numbers
of immunoreactive tumor cells and a consistent
pattern between tumor islands in the upper and lower
portion of the dermis with their frequently different
histological differentiation was not seen. Therefore,
PHLDA1 does not seem to be a suitable marker in
the diagnosis of MAC.
CK15 is one of the most specific follicular bulge
markers available.16 In this study, it highlighted
20/21 DTE and therefore approached the number
of DTE positive for PHLDA1 (21/21). This
is not surprising since PHLDA1 represents an
equally specific follicular bulge marker.17 The
positive staining pattern of DTE for CK15 and
PHLDA1 highlights the follicular nature of this
adnexal neoplasm at the immunohistochemical level.
Whereas PHLDA1 was preferentially expressed in
DTE as opposed to MAC and morpheaform BCC,
CK15 does not reach the discriminatory power that
PHLDA1 has in the differential diagnosis of DTE vs.
morpheaform BCC. In 6/17 morpheaform BCC,
over 75% of the cells were CK15 positive and
in an additional two cases at least less than 26%
of tumor cells in morpheaform BCC were CK15
positive. In 4/9 MAC, the tumor cells were CK15
positive, although at a lower percentage. While
similar for DTE, our staining results for CK15 is
different from the one reported by Hoang et al.5
in respect to MAC and morpheaform BCC. The
authors found the majority of their 13 cases of MAC
to be CK15 positive and all of their infiltrative
morpheaform BCC were CK15 negative. While
on a scale of 3+, 2+ and negative, 10/13 MAC
scored at 2+ and further two cases at 3+, only one
MAC was CK15 negative.5 Differences in antibody
manufacturer, dilution and retrieval may account
for these different results between this study and
the one published by Hoang et al.5 Our antibody
was from Santa Cruz Biotechnology, Santa Cruz,
CA, USA, and was used at a dilution of 1 : 200
whereas Hoang et al.5 employed an antibody from
NeoMarkers, Fremont, CA, USA, at a dilution of
1 : 80. We used standardized heat-induced epitope
retrieval in a citrate buffer at pH 6.0 performed
directly on the Leica Bond-III Automatic Stainer
(Leica Microsystems Ltd). Hoang et al.5 employed
heat-induced epitope retrieval via microwave and in
a buffer not further specified. Antigen retrieval via
microwave is more prone to variable results than
standardized retrieval on an automatic stainer.
CK19 demarcates follicular bulge stem cells but
is not as specific as cytokeratin 15 as it also labels
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transient amplifying cells migrating down the outer
root sheath.16 Thus, it was logically intuitive that
its staining pattern in the three sclerosing neoplasms
studied allowed one to favor one tumor over the
other but did not have the discriminatory power
that some of the other staining results had. Positive
reaction for CK19 favored MAC over DTE and
morpheaform BCC. This is in agreement with this
study that reported a higher percentage of CK19-
positive tumor cells in MAC vs. DTE (morpheaform
BCC was not included in that study).7 In view of
the dual staining of stem cells and their descendent
transient amplifying cells by CK19, we speculate
that the immunoreactivity for CK19 in MAC
reflects its complex nature as opposed to DTE and
morpheaform BCC that show a lower percentage of
staining for CK19.
We conclude that CK15 and CK19 are helpful
adjuncts in the differential diagnosis of sclerosing
adnexal neoplasms but are second in line to BerEP4
and PHLDA1 and propose the algorithm shown
in Fig. 5 for the immunohistochemical work-up of
sclerosing adnexal neoplasms. Not a single marker is
sufficient to differentiate between all of them but a
combination of several antibodies in conjunction
with the clinical presentation and the features
observed on routine histological sections should
enable pathologists to make a definitive diagnosis
when faced with one of these challenging tumors.
The panel of the markers studied represents a useful
adjunct for arriving at the correct diagnosis.
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